Share on StockTwits

Insys Therapeutics (NASDAQ:INSY) Director John N. Kapoor purchased 20,000 shares of the company’s stock on the open market in a transaction dated Wednesday, June 11th. The stock was purchased at an average cost of $24.54 per share, for a total transaction of $490,800.00. Following the purchase, the director now directly owns 15,991 shares in the company, valued at approximately $392,419. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Insys Therapeutics (NASDAQ:INSY) traded up 5.27% during mid-day trading on Friday, hitting $26.35. 693,921 shares of the company’s stock traded hands. Insys Therapeutics has a 52 week low of $7.1467 and a 52 week high of $57.9133. The stock’s 50-day moving average is $30.54 and its 200-day moving average is $35.12. The company has a market cap of $901.9 million and a P/E ratio of 17.74. Insys Therapeutics also saw a significant increase in short interest in May. As of May 30th, there was short interest totalling 5,179,897 shares, an increase of 51.6% from the May 15th total of 3,416,044 shares. Based on an average daily trading volume, of 689,164 shares, the short-interest ratio is currently 7.5 days. Currently, 51.9% of the shares of the stock are short sold.

Insys Therapeutics (NASDAQ:INSY) last released its earnings data on Tuesday, May 13th. The company reported $0.23 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.28 by $0.05. The company had revenue of $41.60 million for the quarter, compared to the consensus estimate of $45.63 million. During the same quarter last year, the company posted $0.01 earnings per share. Insys Therapeutics’s revenue was up 274.8% compared to the same quarter last year. Analysts expect that Insys Therapeutics will post $1.15 EPS for the current fiscal year.

Insys Therapeutics, Inc, is a pharmaceutical company that develops and seeks to commercialize pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.